정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 779 | Terminated | Protective Role of Inhaled Steroids for Covid-19 Infection | Hospitalization in Respiratory Disease Department | Drug: 2: Usual practice + SYMBICORT RAPIHALER Other: 1: Usual practice |
Phase 3 | Assistance Publique - Hopitaux de Paris | OTHER | 146 | All | 18 Years ~ 75 Years | Hopital Bichat - Service de Pneumologie, Paris, France |
| 778 | Not yet recruiting | Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19 | COVID-19 | Biological: Marine liquid and fluids Biological: Impregnation Biological: Incubation Biological: Manipulation Biological: Refrigeration |
Phase 2 | Universidade do Porto, Instituto Politecnico de Braganca | OTHER | 40 | All | 14 Years | Instituto Politecnico de Braganca, Braganca, Portugal ICBAS - University of Porto, Porto, Portugal |
| 777 | Not yet recruiting | Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP | Hepatitis C | Drug: Suboxone Drug: Truvada Drug: Mavyret |
Phase 4 | Duke University | OTHER | 30 | All | 18 Years | Duke Department of Population Health Sciences, Durham, North Carolina, United States NC Survivors Union, Greensboro, North Carolina, United States |
| 776 | Completed | Providing Suboxone and PrEP Using Telemedicine | Hiv | Drug: Suboxone Drug: PrEP |
Phase 4 | Duke University | OTHER | 18 | All | 18 Years | Queen City Needle Exchnge, Charlotte, North Carolina, United States Duke Department of Population Health Sciences, Durham, North Carolina, United States North Carolina Harm Reduction Coalition, Wilmington, North Carolina, United States |
| 775 | Recruiting | Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness | Efficacy and Safety | Drug: Proxalutamide (GT0918) Drug: Placebo |
Phase 3 | Suzhou Kintor Pharmaceutical Inc, | INDUSTRY | 668 | All | 18 Years | Absolute Clinical Research, Phoenix, Arizona, United States Long Beach Clinical Trials, Long Beach, California, United States WR-Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia, United States Olivo Medical and Wellness Center, Chicago, Illinois, United States Gtc Research, Shawnee Mission, Kansas, United States Platinum Research Network, LLC, Metairie, Louisiana, United States Main Street Physician's Care, Little River, South Carolina, United States Lotus Clinical Research, Houston, Texas, United States |
| 774 | Active, not recruiting | Proxalutamide Treatment for COVID-19 Female Outpatients | SARS-CoV Infection | Drug: Proxalutamide Other: Standard of Care |
Phase 3 | Applied Biology, Inc. | INDUSTRY | 200 | Female | 18 Years | Corpometria Institute, Brasilia, Brazil |
| 773 | Recruiting | Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit | SARS (Severe Acute Respiratory Syndrome) | Drug: Proxalutamide Drug: Placebo |
Phase 3 | Applied Biology, Inc. | INDUSTRY | 600 | All | 18 Years | Samel Hospital, Manaus, Amazonas, Brazil |